Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancr...
Dr. Crystal Proud, Pediatric Neurologist at Children’s Hospital of the King’s Daughters, remarked, “Our evolving understanding of...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to d...
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...
Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...
Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) announces its strategic initiative to advance research into Long COVID treatment, unveiling plans ...
Pfizer Inc. has announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union, marki...
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announ...
Celularity's abstract, titled “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferat...
In an interview with BioPharma BoardRoom, Eric Blair, GDMC’s Chief Business Officer, discusses the company's strategic use of Series A funding to pio...
Cencora’s FormularyDecisions has introduced a groundbreaking resource tailored for healthcare payers navigating the evolving landscape of cell and ge...
In a groundbreaking initiative poised to revolutionize cancer treatment, AstraZeneca announces a strategic $300 million investment in a cutting-edge facili...
The Express Genes offering, initially launched in November 2023, now extends to larger midiprep (10μg to 100 μg) and maxiprep (100μg to 1mg) DNA p...
The company's commitment to advancing human potential through science is evident in its transformative approach and a diverse portfolio of specialize...
© 2025 Biopharma Boardroom. All Rights Reserved.
